We are live on
!
Find out more
Theravance Biopharma
TBPH
TBPH
169 hedge funds and large institutions have $927M invested in Theravance Biopharma in 2025 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 72 increasing their positions, 47 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
15,863% more call options, than puts
Call options by funds: $2.55M | Put options by funds: $16K
53% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 47
50% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 18
31% more capital invested
Capital invested by funds: $706M → $927M (+$221M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
4% more funds holding
Funds holding: 162 → 169 (+7)
1.81% more ownership
Funds ownership: 96.06% → 97.87% (+1.8%)
Holders
169
Holders Change
+7
Holders Change %
+4.32%
% of All Funds
2.06%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.06%
New
27
Increased
72
Reduced
47
Closed
18
Calls
$2.55M
Puts
$16K
Net Calls
+$2.54M
Net Calls Change
+$4.22M
Top Buyers
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$5.62M |
| 2 |
Two Sigma Investments
New York
|
+$5.08M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$4.53M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.35M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$3.92M |
